Candel Therapeutics Inc (CADL)
7.97
+0.92
(+13.05%)
USD |
NASDAQ |
May 01, 16:00
7.78
-0.19
(-2.38%)
After-Hours: 20:00
Candel Therapeutics Cash from Investing (TTM): -0.28M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.28M |
September 30, 2023 | -0.529M |
June 30, 2023 | -0.641M |
March 31, 2023 | -1.107M |
December 31, 2022 | -1.297M |
September 30, 2022 | -1.525M |
June 30, 2022 | -1.702M |
Date | Value |
---|---|
March 31, 2022 | -1.777M |
December 31, 2021 | -1.835M |
September 30, 2021 | 18.85M |
June 30, 2021 | 18.51M |
March 31, 2021 | 18.94M |
December 31, 2020 | 38.46M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-1.835M
Minimum
Dec 2021
38.46M
Maximum
Dec 2020
6.467M
Average
-0.641M
Median
Jun 2023
Cash from Investing (TTM) Benchmarks
Allurion Technologies Inc | -1.606M |
AngioDynamics Inc | 124.52M |
Eliem Therapeutics Inc | 68.98M |
Macrogenics Inc | -80.08M |
GlycoMimetics Inc | -0.0214M |